Polyfluorinated compounds acting as bruton tyrosine kinase inhibitors
Described herein is a novel series of multi-fluoro-substituted pyrazolopyrimidine compounds or salts thereof. These compounds are Bruton's tyrosine kinase (BTK) inhibitors. These compounds may possess better BTK inhibition selectivity and pharmacokinetic properties. Disclosed herein are the synthesis methods of these compounds. Disclosed herein are novel synthesis methods of the multi-fluoro-substituted benzophenone and substituted phenoxy benzene. Also disclosed are pharmaceutical compositions comprising the BTK inhibitors described herein. The present invention also relates to pharmaceutical formulations comprising the compounds described herein as active ingredients. The present invention also includes the therapeutic methods by administering the BTK inhibitors and their formulations to treat and inhibit autoimmune disease, hypersensitivity disease, inflammatory diseases and cancer.
1. A compound represented by Formula (I), or an enantiomer, diastereomer or pharmaceutically acceptable salt thereof:
wherein Ar 1 and Ar 2 are represented by Formulae (III) and (IV), respectively:
or are pyrimidine, or quinolone, wherein:
each of A 1 , A 2 , A 3 , A 4 , A 5 , A 6 , A 7 , A 8 , A 9 and A 10 , independently, is C,
each of R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , and R 9 , independently, is selected from H, NO 2 , CF 3 , Cl, or F provided that at least two of R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , and R 9 are F such that the compound is polyfluorinated, and Ar 1 is tetrafluorophenyl, fluorophenyl, pyrimidine, or quinolone,
Q is O,
M 1 is piperidinyl or pyrrolidinyl,
Y is C(═O), S, NR a , and —C(═O)—, wherein R a is acyl, alkyl, alkenyl or alkynyl, and
R 10 is C 2 -C 6 alkenyl or C 2 -C 6 alkynyl, optionally substituted with deuterium, or an enantiomer, diastereomer, prodrug or pharmaceutically acceptable salt thereof.
2. The compound of claim 1 , wherein Ar 1 is represented by the following formula:
3. The compound of claim 1 , wherein Ar 2 is represented by a formula selected from the group consisting of
4. The compound of claim 1 , which is represented by Formula (IX), or an enantiomer, diastereomer or pharmaceutically acceptable salt thereof:
5. The compound of claim 4 , wherein R 1 , R 2 , R 4 and R 5 are F, and R 3 is H.
6. The compound of claim 4 , wherein R 2 is F, and R 1 , R 3 , R 4 and R 5 are H.
7. The compound of claim 1 , wherein M 1 is piperidinyl, and R 10 is vinyl, optionally substituted with deuterium.
8. The compound of claim 2 , wherein M 1 is piperidinyl, and R 10 is vinyl, optionally substituted with deuterium.
9. The compound of claim 3 , wherein M 1 is piperidinyl, and R 10 is vinyl, optionally substituted with deuterium.
10. The compound of claim 4 , wherein M 1 is piperidinyl, and R 10 is vinyl, optionally substituted with deuterium.
11. The compound of claim 1 , wherein M 1 is pyrrolidinyl, and R 10 is vinyl, optionally substituted with deuterium.
12. The compound of claim 2 , wherein M 1 is pyrrolidinyl, and R 10 is vinyl, optionally substituted with deuterium.
13. The compound of claim 3 , wherein M 1 is pyrrolidinyl, and R 10 is vinyl, optionally substituted with deuterium.
14. The compound of claim 4 , wherein M 1 is pyrrolidinyl, and R 10 is vinyl, optionally substituted with deuterium.
15. The compound of claim 1 , wherein R 10 is unsubstituted vinyl or deuterium-substituted vinyl.
16. The compound of claim 1 , which is selected from the group consisting of:
and enantiomers, diastereomers, and pharmaceutically acceptable salts thereof.
17. The compound of claim 1 , which is represented by the following formula:
or an enantiomer, diastereomer, or pharmaceutically acceptable salt thereof.
18. The compound of claim 1 , which is represented by the following formula:
or an enantiomer, diastereomer, or pharmaceutically acceptable salt thereof.
19. The compound of claim 1 , which is represented by the following formula:
or an enantiomer, diastereomer, pharmaceutically acceptable salt thereof.
20. The compound of claim 1 , which is represented by the following formula:
or an enantiomer, diastereomer, or pharmaceutically acceptable salt thereof.
21. The compound of claim 1 , which is represented by the following formula:
or an enantiomer, diastereomer, or pharmaceutically acceptable salt thereof.
22. The compound of claim 1 , which is represented by the following formula:
or an enantiomer, diastereomer, pharmaceutically acceptable salt thereof.
23. The compound of claim 1 , which is represented by the following formula:
or an enantiomer, diastereomer, pharmaceutically acceptable salt thereof.
24. The compound of claim 1 , which is represented by the following formula:
or an enantiomer, diastereomer, pharmaceutically acceptable salt thereof.
25. The compound, enantiomer, diastereomer, or pharmaceutically acceptable salt of claim 1 , wherein the compound, enantiomer, diastereomer, or pharmaceutically acceptable salt inhibits Bruton's tyrosine kinase (BTK) with an IC 50 of 0.5 μM or less.
26. The compound, enantiomer, diastereomer, or pharmaceutically acceptable salt of claim 1 , wherein the compound, enantiomer, diastereomer, or pharmaceutically acceptable salt inhibits BTK with an IC 50 of 0.05 μM or less.
27. A pharmaceutical composition comprising the compound, enantiomer, diastereomer, or pharmaceutically acceptable salt of claim 1 and a carrier.
28. A method for inhibiting BTK activity, comprising administering to a subject in need thereof a therapeutically effective amount of the compound, enantiomer, diastereomer, or pharmaceutically acceptable salt of claim 1 .